Study sponsor: AstraZeneca Pharmaceuticals LP

Location: Enrolled participants do not need to travel.

Purpose of study: The ANCHOR asthma clinical trial is being done by AstraZeneca to assess how well AIRSUPRA reduces severe asthma attacks in adults. AIRSUPRA is an FDA approved rescue inhaler that combines two common asthma medicines (albuterol and budesonide) into a single inhaler that will help treat symptoms and help prevent asthma attacks. Albuterol helps to relax the smooth muscles of the airways, causing the airways to widen, leading to easier breathing. Budesonide helps to decrease inflammation in the lungs.

Participants will use the AIRSUPRA inhaler for 12 months, which will be provided at no cost. Participants will also be asked to complete surveys online every three months and answer questions about your experience with the inhaler over the phone every three months.

If you’re interested and would like to learn more and see if you are eligible to participate, follow the link below.

Click here to learn more about the ANCHOR asthma clinical trial

Inclusion Criteria:
You may be eligible to participate if you meet the following criteria:
– have at least 1 documented asthma diagnosis and prescription for asthma is an albuterol-only OR levalbuterol-only inhaler
– had at least one asthma attack or used an oral steroid for asthma within the last 12 months.
– are not currently pregnant, breastfeeding, or planning to become pregnant with 12 months.
– do not have major respiratory diagnoses in the past 12 months like COPD, cystic fibrosis, etc.
– have not had cancer (not including skin cancer) that was untreated, still being treated, or not in remission in the past 12 months.
– do not use oral corticosteroids like prednisone daily or every other day for more than 21 days in the past 3 months.

Study Contact:
(952) 967-6910
AnchorStudy@HealthPartners.com